Journal Mobile Options
Table of Contents
Vol. 26, No. 2, 2009
Issue release date: October 2009
Fetal Diagn Ther 2009;26:102–106

Intrauterine Treatment of Large Fetal Neck Lymphangioma with OK-432

Mikovic Z. · Simic R. · Egic A. · Stosic Opincal T. · Koprivsek K. · Stanojevic D. · Bogavac M. · Popovac M. · Mandic V.
aDepartment of High-Risk Pregnancies, University Clinic of Gynaecology and Obstetrics ‘Narodni Front’, bDepartment of Plastic and Reconstructive Surgery, Mother and Child Health Care Institute ‘Dr. Vukan Cupic’, and cMR Centre Clinical Centre of Serbia, Belgrade, and dDiagnostic Imaging Centre, Institute of Oncology, Novi Sad University School of Medicine, Sremska Kamenica, and eClinic of Gynaecology and Obstetrics Clinical Centre, Novi Sad University School of Medicine, Novi Sad, Serbia

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Lymphangiomas are benign vascular malformations of the lymphatic system and most commonly present in the neck area. Large lymphangiomas may compress and/or displace the larynx, trachea and esophagus and cause serious respiratory and feeding problems in neonates. Prenatal therapy could eliminate the risks of the mentioned complications. Prenatal therapy may include the EXIT (ex utero intrapartum treatment) procedure. As this procedure has certain risks for both the neonate and mother, the introduction of a safer method is justified. The use of OK-432, as a sclerosing agent, has shown positive results in several published cases of cystic hygroma, but there is no study about the prenatal use of this agent in the treatment of lymphangioma. The aim of this study was to present our experience with intrauterine intralesional injection of OK-432 in the treatment of neck lymphangiomas. Two cases of large multicystic neck lymphangiomas that were closely situated to the fetal airway were treated by single intralesional injection of OK-432. We noticed a progressive decrease in tumor volume throughout gestation. We did not experience any complications and there were no respiratory or feeding problems in the neonates. The esthetical appearance was satisfactory and both children were normal at the age of 2 years and 6 months, respectively. This report suggests that prenatal intralesional injection of OK-432 might be a safe and effective treatment in selected cases with large fetal neck lymphangiomas.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Gallagher PG, Mahoney MJ, Gosche JR: Cystic hygroma in the fetus and newborn. Semin Perinat 1999;23:341–356.
  2. Quinn TM, Hubbard AM, Adzik NS: Prenatal magnetic resonance imaging enhances fetal diagnosis. J Pediatr Surg 1998;33:553–558.
  3. Bouchard S, Johnson MP, Flake AW, Howell LJ, Myers LB, Adzik NS, Crombleholme TM: The EXIT procedure: experience and outcome in 31 cases. J Pediatr Surg 2002;37:418–426.
  4. Ward VMM, Langford K, Morrison G: Prenatal diagnosis of airway compromise: EXIT (ex utero intrapartum treatment) and foetal airway surgery. Int J Pediatr Otorhinolaryngol 2000;53:137–141.
  5. Mota R, Ramalho C, Monteiro J, Correia-Pinto J, Rodrigues M, Guimaraes H, Spratley J, Macedo F, Matias A, Montenegro N: Evolving indications for the EXIT procedure: the usefulness of combining ultrasound and fetal MRI. Fetal Diagn Therapy 2007;22:107–111.
  6. Watari H, Yamada H, Fujino T, Okuyama K, Sagawa T, Makinoda S, Fujimoto S: A case of intrauterine medical treatment for cystic hygroma. Eur J Obstet Gynecol Reprod Biol 1996;70:201–203.
  7. Sasaki Y, Chiba Y: Successful intrauterine treatment of cystic hygroma colli using OK-432. Fetal Diagn Ther 2003;18:391–396.
  8. Ogita K, Suita S, Taguchi T, Yamanouchi T, Masumoto K, Tsukimori K, Nakano H: Outcome of fetal cystic hygroma and experience of intrauterine treatment. Fetal Diagn Ther 2001;16:105–110.
  9. Kuwabara Y, Sawa R, Otsubo Y: Intrauterine therapy for the acutely enlarging fetal cystic hygroma. Fetal Diagn Ther 2004;19:191–194.
  10. Fisher R, Partington A, Dykes E: Cystic hygroma. Comparison between prenatal and postnatal diagnosis. J Pediatr Surg 1996;31:473–476.
  11. Alqahtani A, Nguyen LT, Flageole H, Shaw K, Laberge JM: Twenty-five year’s experience with lymphangiomas in children. J Pediatr Surg 1999;34:1164–1168.
  12. Liechty KW, Crombleholme TM: Management of fetal airway obstruction. Semin Perinatol 1999;23:496–506.
  13. Suzuki N, Tsuchida Y, Takahashi A, Kuroiwa M, Ikeda H, Mohara J, Hatakeyama S, Koizumi T: Prenatally diagnosed cystic lymphangioma in infants. J Pediatr Surg 1998;33:1599–1604.
  14. Claesson G, Kuylenstierna R: OK-432 therapy for lymphatic malformation in 32 patients (28 children). Int J Pediatr Otorhinolaryngol 2002;65:1–6.
  15. Tanemura M, Nishikawa N, Kojima K, Suzuki Y, Suzomori K: A case of successful fetal therapy for congenital chylothorax by intrapleural injection of OK-432. Ultrasound Obstet Gynecol 2001;18:371–375.
  16. Samuel M, McCarthy L, Boddy SA: Efficacy and safety of OK-432 sclerotherapy for giant cystic hygroma in a newborn. Fetal Diagn Ther 2000;15:93–96.
  17. Fujino A, Moriya Y, Morikawa Y, Hoshino K, Watanabe T, Shimojima N, Kitajima M: A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism. J Pediatr Surg 2003;38:1806–1809.
  18. Hall N, Ade-Ajayi N, Brewis C, Roebuck DJ, Kiely EM, Drake DP, Spitz L, Pierro A: Is intralesional injection of OK-432 effective in the treatment of lymphangioma in children? Surgery 2003;133:238–242.
  19. Banieghbal B, Davies MRQ: Guidelines for the successful treatment of lymphangioma with OK-432. Eur J Pediatr Surg 2003;13:103–107.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50